Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2012 08:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, Ublituximab, in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Multi-Center Phase I/II Trial Led by Dr. Owen O'Connor, MD, PhD, Director, Center for Lymphoid Malignancies, New York Presbyterian Columbia Medical Center TG Therapeutics to Host a Conference Call...
August 24, 2012 08:58 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Poster Presentation for Ublituximab (TGTX-1101) at the 7th International Workshop on Waldenstrom's Macroglobulinemia

NEW YORK, Aug. 24, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX) today announced a poster presentation at the 7th International Workshop on Waldenström's Macroglobulinemia (WM),...
August 16, 2012 08:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics and Rhizen Pharmaceuticals Announce Global Agreement for Development and Commercialization of Novel PI3K Delta Selective Inhibitor, TGR-1202

IND Filing Expected Fourth Quarter 2012 Collaboration and Licensing Payments Could Exceed $250MM NEW YORK, Aug. 16, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TG Therapeutics) (OTCBB:TGTX)...
May 14, 2012 16:01 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.

NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (the "Company") - announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug...
April 27, 2012 16:00 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals, Inc. Announces Name Change to TG Therapeutics, Inc. and Reverse Stock Split

NEW YORK, April 27, 2012 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCQB:TGTX) - announced today that is has filed a Certificate of Amendment to its Certificate of Incorporation to change...
March 02, 2012 08:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Completes Licensing Agreement With LFB Biotechnologies for the Development of Ublituximab

NEW YORK, March 2, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. - announced today an agreement with two LFB Group companies, LFB Biotechnologies S.A.S and GTC Biotherapeutics, Inc., to license the...
July 21, 2011 08:00 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals, Inc. Reaches Agreement With the FDA on a Special Protocol Assessment for the Phase 3 Clinical Study of AST-726

NEW YORK, July 21, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAND) announced that the Company has reached an agreement with the U.S. Food and Drug Administration (FDA) on a...
July 13, 2011 16:00 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals, Inc. Announces Reverse Stock Split

NEW YORK, July 13, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) previously announced on Form 8-K that the Company's Certificate of Amendment to its Certificate of...
January 31, 2011 12:11 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Achieves Ariston Merger Milestone

NEW YORK, Jan. 31, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that the company's Board of Directors has decided to continue development of AST-915, an orally...
January 10, 2011 07:35 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Announces Entry Into Settlement and Release Agreement With Nordic Biotech

NEW YORK, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced that on January 4, 2011, the company entered into a settlement and release agreement with Nordic...